Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61L | melanoma | sensitive | CCT241161 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CCT241161 inhibited MEK and ERK activation and growth of a melanoma cell line harboring NRAS Q61L in culture, and inhibited tumor growth in a NRAS Q61L-mutant melanoma cell line xenograft model (PMID: 25500121, PMID: 23431193). | 25500121 23431193 |
PubMed Id | Reference Title | Details |
---|---|---|
(25500121) | Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma. | Full reference... |
(23431193) | Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. | Full reference... |